TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~2. Histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.~3. At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.~4. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose~Key Exclusion Criteria:~1. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤grade 1 of CTCAE v5.0~2. Uncontrolled tumour-related pain~3. Known central nervous system (CNS)~4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures~5. Use of inhaled corticosteroids~6. Known history of autoimmune disease~7. Use of any live attenuated vaccines within 28 days~8. Have severe cardiovascular disease~9. Uncontrolled or severe illness~10. History of immunodeficiency disease~11. Active malignancies which are likely to require the treatment.~12. Child-bearing potential female~13. Have psychiatric illness or disorders~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LM-108 Dose Escalation (Type: EXPERIMENTAL): Drug: LM-108 Administered intravenously
- LM-108 Dose Expansion (Type: EXPERIMENTAL): Drug: LM-108 Administered intravenously
- LM-108 Combination Dose Escalation (Type: EXPERIMENTAL): Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
- LM-108 Combination Dose Expansion (Type: EXPERIMENTAL): Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy électrochimique cutanée

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult~Exclusion Criteria:~* Patients group : Not have a chronic neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test (Type: ACTIVE_COMPARATOR): 2000 patients healthy in anesthesiology consultation
- Patients (Type: EXPERIMENTAL): 2000 patients in pain clinic consultation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Infertility requiring intrauterine insemination~* Age: 25-40 (at time of enrollment)~* Intact Normal Ovaries (Both)~* Early follicular phase (day 2-4) serum FSH level \< 20 mIU/ml~* Diagnosis of infertility with a recommended treatment of ovarian stimulation and IUI~Exclusion Criteria:~* BMI \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level ≥ 20 mIU/ml~* Overstimulated cycle: \>3 mature follicles (≥17 mm)~* Abnormal uterine cavity and /or tubal blockage~* Diagnosis of infertility with a clear indication for IVF~* Severe male factor infertility: Total Motile Sperm Count \< 2x106 post washing

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Nimodipine (Type: EXPERIMENTAL): Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
- Placebo (Type: PLACEBO_COMPARATOR): Same as for nimodipine but an identical placebo will be self-administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* low grade B cell lymphoma~* 1 or more sites of disease appropriate for intratumoral injection~* measurable disease other than the injection site~* Performance Status of 1 or better~* Adequate bone marrow, renal and hepatic function~* No active autoimmune disease or systemic immunosuppressive drugs~* Life expectancy \> 4 months~Exclusion Criteria:~* Known HIV~* Known brain metastases~* Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)~* Anticoagulation therapy other than 325mg QD ASA~* Significant cardiovascular disease~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VTX-2337 plus radiation (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise healthy adults aged 18 to 50 years, inclusive~* No history of significant ME disease~* No history of past ME surgeries~* Able to comprehend study risks and provide written Informed Consent~Exclusion Criteria:~* Have any chronic health problem~* Have ME fluid or otitis media (OM)at the time of presentation~* Have drainage through the tympanostomy tube at the time of testing~* Taking any prescription drug with the exception of those for birth control that would interfere with study per study MD~* Have a known or suspected allergy/adverse reaction to any of the study drugs use to prepare the tympanic membrane for ventilation tube insertion or the nasopharynx for EMG needle insertion~* Have a hearing threshold \>15 dB or a \>10 dB air-bone gap at any of the speech frequencies~* Pregnant or nursing~* Temporary exclusion: expected need for seasonal allergy med during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- healthy adults (Type: EXPERIMENTAL): Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cetrotide Treatment Optimization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normo-ovulatory women \< 39 years with an indication for IVF or ICSI~Exclusion Criteria:~* More than 2 previous unsuccessful IVF/ICSI cycles~* BMI \> 32 kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- CD2 (Type: EXPERIMENTAL): Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
- CD6 (Type: EXPERIMENTAL): Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Singleton pregnancy~* GDM diagnosed during pregnancy according to IADPSG criteria~* Self-monitoring of blood glucose~* After at least 7 days of dietary and lifestyle measures, unreached post-prandial glucose control~* 14-37 (+ 6 days) amenorrhea weeks at the time of randomization~* Signed informed consent~Exclusion Criteria:~* Prandial insulin use before randomization during this pregnancy~* Use of other oral hypoglycemic agents during this pregnancy~* Multiple pregnancy~* Known hepatic insufficiency~* Long time corticosteroid treatment~* Pre-existing diabetes in pregnancy~* Overt diabetes diagnosed during pregnancy (IADPSG criteria)~* Lack of Social Insurance~* Insufficient understanding~* Participant in another investigational drug study at inclusion visit~* Contraindications of acarbose~* Fetal malformation diagnosed by previous fetal ultrasound

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- acarbose (Type: EXPERIMENTAL): The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
- prandial insulin (Type: ACTIVE_COMPARATOR): The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Costa Rican Natural History Study of HPV and Cervical Neoplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA FOR FOLLOW-UP PHASE OF NATURAL HISTORY STUDY:~Less than 35 years of age.~Intact uterus (non-hysterectomized).~In good general health.~Non-pregnant.~For women not using OCs: Having regular cycles \[cycles 25-35 days in length\].~HPV16 seropositive \[based on data from latest visit tested\].~No evidence of HSIL/cancer \[based on data from latest visit within cohort\].~Willing to participate \[informed consent\].~INCLUSION CRITERIA FOR FOLLOW-UP PHASE OF COHORT STUDY:~Must be between the ages of 45 to 70 years.~Women who do not have a final diagnosis of HSIL.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Women in Costa Rica (Type: None): Examining the natural history of HPV and cervical neoplasia in Costa Rican women.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years at the time of recruitment~* treatment with Elexacaftor-Tezacaftor-Ivacaftor for \> 90 days prior to enrollment~* willing to continue twice daily airway clearance for a minimum of 90 days and up to180 days if enrolled in the continuing treatment arm~* no exacerbations in the last 28 days~Exclusion Criteria:~* active smoking or vaping (tobacco, marijuana, recreational drugs)~* recent change in chronic airway clearance regimen with the last 28 days~* inability to tolerate airway clearance or intolerance to either/or hypertonic saline and Pulmozyme~* current treatment for an acute pulmonary exacerbation~* ongoing therapy for Nontuberculous Mycobacterium (NTM)~* investigational drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptom driven (Type: EXPERIMENTAL): Symptom driven performance of airway clearance regimen
- Continuous (Type: ACTIVE_COMPARATOR): Continuous performance of baseline daily airway clearance regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The treatment vessel is DeNovo~* Stenotic (\>50%) or occlusive atherosclerotic disease of infrapopliteal artery(s)~* Length of target lesion is \> 50 mm~* Reference target vessel diameter between 2-4.0 mm by visual assessment~* Documented Rutherford Class 4 or 5 symptomatic critical limb ischemia~* The patient must be \>18 years of age~* Life-expectancy of more than 12 months~* The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure~* The patient must be willing and able to return to the appropriate follow-up times for the duration of the study~* The patient must provide written patient informed consent that is approved by the ethics committee~* Anatomic Inclusion Criteria~  * All inflow lesions successfully (\<30 residual stenosis) treated prior to target lesion treatment during same procedure or according standard of care without unresolved complications~ * At least one angiographically visible target at the ankle for establishment of straight line flow.~Exclusion Criteria:~* Patient refusing treatment~* The target vessel segment diameter is not suitable for available catheter design.~* Unsuccessfully treated endovascular or bypass( \>30% residual stenosis) proximal ( iliac, SFA, popliteal) inflow limiting arterial/graft stenosis~* Lesion lies within or adjacent to an aneurysm~* The patient has a known allergy to heparin, Aspirin or other antiaggregant therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.~* The patient has a history of prior life-threatening contrast media reaction.~* The patient is currently enrolled in another investigational device or drug trial.~* The patient is currently breast-feeding, pregnant or intends to become pregnant.~* The patient is unable to provide informed consent~* The patient has end stage renal disease (currently on any form of dialysis)~* Known Left Ventricular Ejection Fraction \< 35%~* The patient has had an MI within 30 days prior to enrollment~* The patient has had a CVA within 90 days prior to enrollment~* Serum Creatinine \> 150 µmol~* The patient has a previous bypass in the target limb~* The patient has a current systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older~* Confirmed pancreatic ductal adenocarcinoma~* Metastatic disease as documented by CT scan or MRI (locally advanced disease only NOT eligible)~* At least 1 site of disease measurable by RECIST ver1.1~* ECOG performance status of 0 to 1~* Adequate bone marrow, renal capacity and hepatic function~* Willing to administer daily subcutaneous injections at home~Exclusion Criteria:~* Any prior radiotherapy, chemotherapy, surgery, or investigational therapy for adjuvant or metastatic pancreatic cancer~* History of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis)~* History of unexplained bleeding episodes within 3 months of M402 dosing~* Received thrombolytic agents w/in the previous month~* Had full-dose anticoagulation with heparin, enoxaparin, dalteparin, other LMWH, a/or other anticoagulants w/in 90 days before first dose of M402~* High cardiovascular risk, including but not limited to, recent coronary stenting or myocardial infarction in the past year~* Major trauma or surgery w/in prior 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nab-paclitaxel, gemcitabine, placebo (Type: PLACEBO_COMPARATOR): Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle.
- nab-paclitaxel, gemcitabine, necuparanib (Type: EXPERIMENTAL): Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Cardiac Output Before and After Cardiopulmonary Bypass.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \> 21 years~* Patients undergoing surgery involving cardiopulmonary bypass~* Patients instrumented with a thermodilution catheter~Exclusion Criteria:~* Patients aged \< 21 years~* Patients undergoing surgery off pump (not involving cardiopulmonary bypass)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CASAD for Severe Diarrhea in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients presenting to the EC or an acute care clinic for NCI grade \>/= 2 diarrhea~2. Able to understand the description of the study and give informed consent~3. Patients must be willing to and capable of providing frequent assessments for the duration of the study~4. English-speaking~Exclusion Criteria:~1. Patients will not be approached while they have : a) evidence of fever or severe abdominal pain, melena, overt blood in stool; b) any clinical suspicion or evidence of peritonitis or bowel perforation; c) s/p allogenic stem cell transplant~2. Patients will not be approached if the EC physician thinks that the diarrhea is due to Crohn's disease, ulcerative colitis, Celiac disease, graft-versus-host disease, short-gut syndrome, neuroendocrine paraneoplastic syndromes (e.g., MEN, VIPomas, etc.), or malabsorption syndromes~3. Patients who are status post stem cell transplantation (both autologous or allogenic)~4. Patients who are status post immunotherapy (including those who are receiving or have received ipilimumab)~5. Patients participating in other clinical trials for diarrhea~6. Patients with a known allergy to any components of the CASAD formulation~7. Patients whose current medication schedule would not permit an approximate 2 hour window between administration of CASAD and other scheduled medications~8. Patients who cannot comply with medications~9. Patients taking any clay products~10. Patients with radiological evidence of megacolon, intraperitoneal free air, pneumatosis intestinalis, or fecal impaction~11. History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up~12. Patients who are pregnant~13. Patients less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcium Alumina-Silicate (CASAD) (Type: EXPERIMENTAL): CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues